203 results on '"Mezzanzanica D"'
Search Results
2. Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
3. 37 Reducing overtreatment of early stage ovarian cancer: strategies implementation by a mirna-driven prognostic assessment
4. The deubiquitinase USP8 regulates ovarian cancer cell response to cisplatin by suppressing apoptosis
5. Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein
6. 23 Impact of COVID-19 in gynecologic oncology: a nationwide Italian survey
7. Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies
8. Studies of the IL-18/IL-18 binding-protein system in human ovarian cancer reveal potential mechanisms of tumor escape: W61.003
9. Enhancing ovarian cancer conventional chemotherapy through the combination with cannabidiol loaded microparticles
10. A critical comparison of three internalization assays applied to the evaluation of a given mAb as a toxin-carrier candidate
11. A Step Further in Understanding the Biology of the Folate Receptor in Ovarian Carcinoma
12. 37 Reducing overtreatment of early stage ovarian cancer: strategies implementation by a mirna-driven prognostic assessment
13. In nostro fantastico sistema immuntario
14. Human Carcinoma Cell Lines Xenografted in Athymic Mice: Biological and Antigenic Characterization of an Intra-Abdominal Model
15. Gene expression profiling of advanced ovarian cancer: characterizazion of a molecular signature involving the fibroblast growth factor 2 signaling
16. 433: An integrated multi level ‘-omics’ approach to decipher disease recurrence in epithelial ovarian cancer
17. Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy
18. Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer
19. 857 MicroRNA Predictor of Early Relapse in Advanced Stage Ovarian Cancer Patients
20. 544 Aberrant choline metabolism in epithelial ovarian cancer: relevance of choline kinase activity and expression
21. 123 MicroRNA profile associated to clinical response in ovary cancer: biological/clinical implications
22. 378 Aberrant phosphatidylcholine metabolism as source of biomarkers and therapeutic targets in human ovarian cancer
23. Targeting of T or NK lymphocytes against tumor cells by bispecific monoclonal antibodies: role of different triggering molecules
24. Effect of complement activation induced by chimeric anti-Folate receptor antibodies for the treatment of residual disease of ovarian carcinoma
25. Preparation and characterization of blocked and no-blocked conjugates consisting of ricin and a tumor-specific non-internalizing MAb
26. Bonding characteristics of newly developed all‐in‐one adhesives
27. Effect of Different Bur Grinding on the Bond Strength of Self–etching Adhesives
28. Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy.
29. Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.
30. Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth.
31. Activation of p185her2 in the human lung adenocarcinoma cell line Calu3
32. Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells.
33. Human ovarian carcinoma lysis by cytotoxic t cells targeted by bispecific monoclonal antibodies: Analysis of the antibody components.
34. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity.
35. Antibody-toxin conjugate preparation: effects of the linker on activity and stability
36. Aberrant phosphatidylcholine metabolism as source of biomarkers and therapeutic targets in human ovarian cancer
37. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients
38. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients
39. Possible targets on carcinoma for bMAb retargeting of lymphocyte or drug cytotoxicity
40. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells
41. Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection
42. Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation
43. Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups
44. Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment
45. Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab
46. Prognostic Evidence of the miRNA-Based Ovarian Cancer Signature MiROvaR in Independent Datasets
47. Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein
48. Activation of p185 her2 in the human lung adenocarcinoma cell line Calu3
49. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Sex Cord Stromal Tumors
50. High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.